Rite Aid Corporation Falls: Did The News Warrant The Response?

Rite Aid Corporation saw significant losses on Thursday after two years of market-leading gains, therefore its possible that its revised outlook is not a sign of long-term weakness, but rather produced a value opportunity.

Jun 6, 2014 at 5:30PM
Rite Aid

Rite Aid Corporation (NYSE:RAD) lost up to 10% of its valuation on Thursday June 5, 2014 after the company revised guidance downward. The company's outlook revolves around partner McKesson Corporation (NYSE:MCK), and is viewed as especially alarming given the incredible fundamental data of peer Walgreen Company (NASDAQ:WBA) on Wednesday. Nonetheless, investors are reacting harshly to the news, but does this reaction create an investment opportunity?

A solvable problem?
According to Rite Aid, its profit for both the current quarter and fiscal 2015 is expected to be below prior estimates. Rite Aid notes that higher-than-expected drug costs are to blame .

Specifically, there is a delay in price reductions for the generic drugs that Rite Aid is attempting to purchase, and reimbursement rates are taking longer than anticipated. As Jim Cramer noted, this is a direct issue with partner McKesson involving generics, or a mishap in the supply chain.

McKesson essentially acts as a middleman for Rite Aid and other pharmacies, by processing, purchasing, and then shipping new and current generic drugs from the supplier to the pharmacy; several months ago, Rite Aid enhanced its partnership with McKesson.

Now, in retrospect this news is not all that surprising. As explained in a previous article , the pharmacy business is right in the middle of an enormous transition where $133 billion in brand-drug sales lose patent protection, and new generics are introduced. While this bodes well for pharmacies in terms of profitability, it also poses a challenge, as generics are purchased in bulk and often require more scale.

Patent Cliff

Not to mention, 2014 was already expected to be a significant year for new generic introductions, with $12.6 billion in branded blockbuster drugs sales losing patent protection. This, combined with prior years of patent expirations, essentially proves that 2014 was going to have some challenges, but with McKesson being a top distribution company, it's a problem that's undoubtedly solvable.

Moreover, this problem on behalf of McKesson proves that volume is high for the company, which is a positive for shareholders.

What's the impact?
So, to what degree will this news affect Rite Aid? According to the company, it now expects net income between $298 and $408 million for the year, or an EPS of $0.30 to $0.40 per diluted share. Now, here's the kicker: Rite Aid's prior guidance was for an EPS of $0.31 to $0.41, meaning that Rite Aid has essentially lowered its full-year outlook by less than $10 million. Yet, this $10 million differential has been responsible for valuation losses in excess of $700 million!

Clearly, the math doesn't add up, but when you consider that Rite Aid is still up more than 650% from its 2012 stock lows, it might have been due for a pullback. This is a company that has beat analyst expectations in each of the last six quarters, and has revised guidance upwards on many occasions. Therefore, investors had high expectations for Rite Aid.

High expectations are well-deserved
In addition to Rite Aid having such high expectations, Walgreen's 6% increase in revenue during the month of May probably didn't help Rite Aid much, as it shows weakness in an industry that is apparently performing beyond all expectations. However, it's worth noting that Rite Aid announced a same-store sales increase of 3.5% in the May , adding to the 4.9% increase it saw in April, and further showing that Rite Aid, like Walgreen, is now a growth company.

In regards to Walgreen, its stock has more than doubled since 2013, and at 26.5 times earnings, it too has high expectations. While the high hopes are well deserved, Rite Aid's distribution problem with generics appear to be macro-related, and it'll be interesting to see if Walgreen also experiences some EPS pressure.

Foolish Thoughts
If you step back and actually read Rite Aid's updated outlook, it's really not that bad, and there are no reasons to believe it's a long-term problem. Moreover, it's a rather insignificant problem from a fundamental perspective, therefore Rite Aid's reaction is more based on panic, rather than the actual meaning of the news.

Albeit, at 0.32 times sales Rite Aid remains far cheaper than its two larger peers, and continues to report large profits. Therefore, with a surplus of new generics hitting the market, investors have to like Rite Aid's prospects long-term, and the value created with Thursday's loss.

Rite Aid gains from innovation in health care, and the following medical solution could be the most exciting in years!
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.


 

Brian Nichols owns shares of Rite Aid. The Motley Fool recommends McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers